![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZCCHC2 |
Gene summary for ZCCHC2 |
![]() |
Gene information | Species | Human | Gene symbol | ZCCHC2 | Gene ID | 54877 |
Gene name | zinc finger CCHC-type containing 2 | |
Gene Alias | C18orf49 | |
Cytomap | 18q21.33 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9BRD4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54877 | ZCCHC2 | NAFLD1 | Human | Liver | NAFLD | 2.84e-07 | 8.19e-01 | -0.04 |
54877 | ZCCHC2 | S43 | Human | Liver | Cirrhotic | 5.03e-08 | -5.95e-02 | -0.0187 |
54877 | ZCCHC2 | HCC1_Meng | Human | Liver | HCC | 1.15e-60 | 7.92e-02 | 0.0246 |
54877 | ZCCHC2 | HCC2_Meng | Human | Liver | HCC | 1.53e-08 | -7.73e-02 | 0.0107 |
54877 | ZCCHC2 | HCC2 | Human | Liver | HCC | 7.58e-09 | 3.10e+00 | 0.5341 |
54877 | ZCCHC2 | S028 | Human | Liver | HCC | 8.91e-04 | 3.35e-01 | 0.2503 |
54877 | ZCCHC2 | S029 | Human | Liver | HCC | 1.80e-02 | 3.76e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | ![]() |
Stomach | SIM | ![]() |
Liver | NAFLD | ![]() |
Liver | Cirrhotic | ![]() |
Liver | HCC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZCCHC2 | SNV | Missense_Mutation | c.2704N>G | p.Leu902Val | p.L902V | Q9C0B9 | protein_coding | tolerated(0.07) | benign(0.081) | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD | |
ZCCHC2 | SNV | Missense_Mutation | c.1573N>A | p.Pro525Thr | p.P525T | Q9C0B9 | protein_coding | deleterious(0.01) | benign(0.115) | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZCCHC2 | SNV | Missense_Mutation | novel | c.2270C>T | p.Ala757Val | p.A757V | Q9C0B9 | protein_coding | tolerated(0.21) | benign(0.34) | TCGA-AR-A2LN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
ZCCHC2 | SNV | Missense_Mutation | c.1486N>C | p.Glu496Gln | p.E496Q | Q9C0B9 | protein_coding | deleterious(0.01) | possibly_damaging(0.782) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZCCHC2 | SNV | Missense_Mutation | c.2413N>G | p.Thr805Ala | p.T805A | Q9C0B9 | protein_coding | tolerated(0.45) | benign(0) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
ZCCHC2 | insertion | Frame_Shift_Ins | novel | c.3269_3270insTTACA | p.Met1090IlefsTer29 | p.M1090Ifs*29 | Q9C0B9 | protein_coding | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
ZCCHC2 | insertion | In_Frame_Ins | novel | c.1019_1020insCACACCTGTAATTCCAGCACTTTGGGA | p.Thr341_Val342insProValIleProAlaLeuTrpAspThr | p.T341_V342insPVIPALWDT | Q9C0B9 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ZCCHC2 | SNV | Missense_Mutation | rs770818627 | c.3368N>T | p.Ser1123Leu | p.S1123L | Q9C0B9 | protein_coding | tolerated(0.07) | benign(0.17) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZCCHC2 | SNV | Missense_Mutation | novel | c.3518N>T | p.Thr1173Met | p.T1173M | Q9C0B9 | protein_coding | deleterious(0.01) | possibly_damaging(0.642) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZCCHC2 | SNV | Missense_Mutation | rs770818627 | c.3368N>T | p.Ser1123Leu | p.S1123L | Q9C0B9 | protein_coding | tolerated(0.07) | benign(0.17) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |